communityacquir
pneumonia
continu
import
complic
hiv
infect
rate
pneumonia
decreas
use
antiretrovir
therapi
continu
higher
hiv
uninfect
individu
risk
factor
pneumonia
includ
low
blood
count
unsuppress
plasma
hiv
load
smoke
inject
drug
use
renal
impair
immun
streptococcu
pneumonia
smoke
cessat
reduc
risk
unclear
whether
newli
report
viral
respiratori
pathogen
middl
east
respiratori
syndrom
coronaviru
problem
hivinfect
individu
gener
popul
communityacquir
pneumonia
cap
remain
import
caus
morbid
mortal
hivposit
individu
although
incid
decreas
use
antiretrovir
therapi
art
rate
continu
elev
compar
hivuninfect
individu
develop
develop
societi
clinic
present
rang
typic
pathogen
outcom
cap
similar
without
hiv
infect
import
differenti
diagnos
implic
futur
health
merit
particular
attent
hivinfect
individu
review
consid
evid
concern
cap
hivinfect
individu
particular
emphasi
studi
report
last
year
consid
role
bacteri
viral
caus
pneumonia
condit
mimic
pneumonia
manag
hospitalacquir
pneumonia
infect
caus
opportunist
pathogen
pneumocysti
jirovecii
cmv
fungal
mycobacteri
organ
cover
elsewher
discuss
beyond
stress
present
acut
pneumon
ill
henc
often
need
consid
part
differenti
diagnosi
prior
develop
effect
art
respiratori
tract
infect
common
complic
hiv
infect
advent
art
associ
substanti
declin
rate
opportunist
infect
frequenc
pulmonari
infect
p
jirovecii
pneumonia
fallen
bacteri
pneumonia
becom
increasingli
promin
care
hivinfect
peopl
although
debat
increas
rate
pneumonia
hivinfect
person
follow
art
recent
data
sever
larg
observ
cohort
significantli
increas
current
knowledg
subject
patient
cohort
multicentr
aid
cohort
studi
mac
women
interag
hiv
studi
wih
follow
sinc
respect
allow
analysi
rate
pneumonia
art
era
mac
cohort
adjust
odd
ratio
bacteri
pneumonia
compar
hivuninfect
individu
declin
preart
period
follow
introduct
art
wih
cohort
hivinfect
women
also
shown
elev
incid
pneumonia
despit
art
use
adjust
odd
ratio
compar
hivuninfect
control
similarli
veteran
age
cohort
studi
involv
virtual
cohort
hivinfect
individu
use
data
us
nation
va
health
inform
system
date
hiv
diagnosi
rate
per
personyear
found
hivinfect
individu
compar
per
personyear
hivneg
control
lower
incid
seen
eurosida
studi
patient
countri
studi
incid
pneumonia
personyear
found
may
reflect
better
immun
statu
particip
latter
era
mean
blood
count
low
level
sever
bacteri
infect
demonstr
eurosida
studi
count
level
gener
regard
near
normal
studi
popul
europ
us
confirm
import
bacteri
pneumonia
hivinfect
individu
recent
work
taiwan
show
common
respiratori
complic
hiv
infect
count
howev
gener
improv
incid
rate
found
popul
surveil
data
soweto
south
africa
indic
persist
high
rate
invas
pneumococc
diseas
decreas
sinc
introduct
art
may
due
high
level
immunocompromis
popul
despit
avail
art
although
increas
invas
pneumococc
diseas
found
amongst
women
studi
suggest
gener
uptak
childhood
pneumococc
conjug
vaccin
pcv
form
part
childhood
immun
schedul
south
africa
may
particularli
effect
reduc
rate
invas
pneumococc
diseas
amongst
hivinfect
adult
commun
specif
risk
factor
cap
identifi
cohort
studi
studi
shown
pneumonia
common
hivinfect
peopl
level
immunosuppress
rate
pneumonia
increas
increas
immunosuppress
cigarett
smoke
consist
report
increas
risk
pneumonia
hazard
ratio
former
smoker
compar
current
smoker
cohort
studi
franc
inject
drug
use
increas
risk
pneumonia
although
may
due
confound
diseas
poor
adher
art
socioeconom
factor
recent
evid
suggest
direct
effect
opiat
withdraw
may
play
role
ethnic
differ
pneumonia
rate
may
reflect
socioeconom
factor
found
cohort
rate
pneumonia
africanamerican
california
significantli
higher
ethnic
group
aborigin
ethnic
risk
factor
invas
pneumococc
diseas
canada
asian
ethnic
associ
reduc
risk
evalu
subcutan
esprit
trial
caregiv
young
children
high
rate
pneumococc
carriag
may
predispos
invas
pneumococc
diseas
recent
studi
south
africa
confirm
signific
childtomoth
transmiss
pneumococc
strain
eurosida
studi
show
reduc
estim
glomerular
filtrat
rate
egfr
signific
risk
factor
sever
bacteri
infect
includ
pneumonia
incid
rate
ratio
egfr
compar
egfr
clear
direct
effect
immun
function
caus
renal
impair
result
comorbid
condit
lifestyl
factor
art
import
protect
factor
pneumonia
sever
cohort
demonstr
suppress
hiv
load
associ
lower
incid
pneumonia
recent
icona
studi
itali
show
overal
incid
per
personyear
increas
risk
peopl
low
nadir
count
low
current
count
high
viral
load
trial
follow
individu
median
month
aid
diagnosi
prior
art
initi
nadir
count
low
nadir
count
associ
hazard
ratio
episod
bacteri
pneumonia
per
higher
low
current
blood
associ
hazard
ratio
per
higher
unsuppress
plasma
viral
load
associ
hazard
ratio
strategi
manag
antiretrovir
therapi
smart
trial
demonstr
reduct
incid
pneumonia
continu
compar
intermitt
art
well
lower
incid
undetect
plasma
hiv
load
trial
recruit
patient
count
intermitt
rather
continu
art
associ
increas
pneumonia
incid
find
particular
import
random
trial
methodolog
intermitt
versu
continu
art
allow
confid
observ
differ
pneumonia
incid
result
art
rather
unmeasur
confound
factor
esprit
trial
evalu
effect
subcutan
hivinfect
patient
start
art
count
also
found
higher
hiv
plasma
viral
load
associ
increas
risk
pneumonia
hazard
ratio
log
higher
viral
load
reduct
pneumonia
incid
also
report
hivinfect
children
us
attribut
use
art
pneumococc
vaccin
observ
cohort
studi
hivinfect
children
observ
show
lower
count
pneumonia
without
pneumonia
cell
multivari
analysi
hiv
viral
load
copiesml
associ
hazard
ratio
pneumonia
work
hivuninfect
popul
suggest
use
statin
hmg
coenzym
reductas
inhibitor
may
reduc
pneumoniarel
mortal
possibl
attenu
associ
inflammatori
respons
howev
recent
studi
netherland
use
populationbas
data
found
neither
reduct
frequenc
pneumonia
wors
outcom
occur
hivinfect
individu
take
regular
statin
therapi
rememb
higher
incid
pneumonia
hivinfect
individu
mean
present
cap
prompt
consider
hiv
test
patient
known
hivinfect
estim
around
hivinfect
popul
uk
hivinfect
popul
us
unawar
serostatu
survey
subsaharan
africa
undertaken
usaid
shown
mani
countri
major
hivinfect
individu
know
serostatu
bacteri
pneumonia
regard
indic
condit
must
prompt
discuss
hiv
test
british
hiv
associ
guidelin
recommend
patient
admit
bacteri
pneumonia
offer
hiv
test
analysi
primari
care
data
confirm
bacteri
pneumonia
one
strongest
indic
condit
hiv
infect
invas
pneumococc
diseas
particularli
strongli
associ
hiv
infect
recent
uk
populationbas
data
show
patient
invas
pneumococc
diseas
undiagnos
hiv
infect
recent
studi
contribut
understand
pathogenesi
pneumonia
hivinfect
individu
although
deplet
cell
hallmark
hiv
infect
recogn
impair
innat
immun
respons
play
import
role
increas
suscept
pneumonia
reduc
tcell
respons
respiratori
antigen
demonstr
bronchoalveolar
cell
compar
hivuninfect
control
disrupt
tcell
respons
pneumococcu
appear
preced
tcell
deplet
hiv
caus
chronic
activ
dendrit
cell
innat
immun
system
trigger
immun
dysregul
apoptosi
cell
impair
tcell
respons
may
also
import
level
found
predict
pneumonia
hiv
epidemiolog
research
studi
hivinfect
women
us
adjust
age
cell
count
viral
load
antiretrovir
use
impair
immun
respons
within
lung
hivinfect
individu
result
chang
oral
airway
microbiota
increas
number
divers
microorgan
includ
potenti
pathogen
speci
found
hivinfect
patient
pneumonia
compar
hivneg
control
hivinfect
individu
appear
particularli
suscept
pneumococc
diseas
rate
carriag
streptococcu
pneumonia
found
higher
hivinfect
individu
prospect
cohort
hivinfect
hivuninfect
mother
zambia
although
note
count
subject
known
smoke
appear
increas
rate
pneumococc
carriag
lower
nadir
count
aid
diagnos
may
interact
respiratori
viral
pathogen
rate
invas
pneumococc
diseas
influenza
infect
report
associ
increas
blood
pneumococc
load
viral
pathogen
respons
larg
proport
respiratori
tract
infect
hivinfect
individu
although
limit
data
avail
role
viral
pathogen
prospect
studi
montreal
found
among
hivposit
patient
fever
symptom
consist
respiratori
tract
infect
virus
account
ill
studi
patient
art
median
cell
count
median
viral
load
copiesml
influenza
import
viral
caus
respiratori
tract
infect
identifi
viral
infect
due
influenza
equal
number
influenza
b
virus
isol
human
metapneumoviru
type
b
respiratori
syncyti
viru
parainfluenza
type
coronaviru
pathogen
also
caus
respiratori
tract
infect
hivuninfect
individu
known
incid
sever
infect
differ
hivinfect
individu
although
respiratori
syncyti
viru
report
caus
sever
cap
hivposit
individu
although
often
suggest
hivinfect
individu
may
suscept
viral
respiratori
tract
infect
suffer
sever
diseas
associ
viral
pathogen
evid
support
mix
studi
prior
avail
art
suggest
hivinfect
individu
sever
diseas
due
influenza
infect
cohen
et
al
report
excess
mortal
amongst
hivinfect
person
influenza
epidem
period
south
africa
us
reduct
excess
mortal
sinc
widespread
use
art
us
howev
clear
excess
mortal
aris
directli
influenza
infectionfor
exampl
observ
studi
barcelona
found
differ
sever
influenza
patient
without
hiv
infect
admit
influenza
h
n
excess
death
influenza
epidem
period
found
cohen
et
al
may
instead
result
condit
preval
time
includ
pneumococc
pneumonia
gener
data
h
n
pandem
support
suggest
hivinfect
individu
experi
sever
diseas
emerg
respiratori
pathogen
middl
east
respiratori
syndrom
coronaviru
mer
cov
may
pose
threat
everybodi
data
yet
avail
rel
suscept
hivinfect
individu
condit
possibl
antiretrovir
medic
may
modifi
present
influenza
infect
proteas
inhibitor
shown
block
influenza
viral
replic
although
clinic
impact
observ
remain
unclear
hivinfect
individu
pneumonia
present
typic
clinic
featur
acut
ill
character
fever
pleurit
chest
pain
breathless
hypoxaemia
use
establish
sever
score
found
valid
hiv
infect
pneumonia
sever
index
psi
beststudi
score
system
assess
sever
predict
likelihood
mortal
confirm
recent
studi
california
although
manag
cap
hivinfect
person
specif
exclud
pneumonia
guidelin
us
europ
treatment
follow
similar
principl
patient
without
hiv
infect
patient
high
psi
score
signific
risk
death
manag
critic
care
area
possibl
typic
bacteri
pathogen
similar
hivneg
popul
pneumonia
consist
found
common
pathogen
signific
pathogen
includ
haemophilu
influenza
klebsiella
pneumonia
staphylococcu
aureu
moraxella
catarrhali
pseudomona
aeruginosa
atyp
organ
legionella
pneumophila
mycoplasma
spp
chlamydia
pneumonia
repres
less
case
although
incid
infect
hivinfect
peopl
systemat
evalu
rememb
opportunist
pathogen
p
jirovecii
cryptococcu
neoforman
present
acut
pneumon
ill
consid
differenti
diagnosi
pneumonia
immunocompromis
individu
incid
mycobacterium
tuberculosi
infect
greatli
increas
hivinfect
individu
present
clinic
radiolog
featur
ident
bacteri
pneumonia
fig
choic
empir
antibiot
treatment
differ
popul
depend
local
antibacteri
drug
resist
rate
penicillin
resist
pneumonia
europ
rang
data
suggest
antibiot
resist
respiratori
pathogen
may
higher
hivinfect
individu
find
may
relat
use
cotrimoxazol
pneumocysti
pneumonia
prophylaxi
differ
serotyp
infect
hivposit
individu
mortal
rate
cap
differ
among
publish
seri
fall
rang
case
although
subject
controversi
mortal
length
hospit
stay
hivinfect
person
pneumonia
seem
differ
patient
without
hiv
infect
note
data
aris
us
europ
may
applic
resourcelimit
set
recent
studi
ad
evid
blood
count
predict
mortal
use
guid
therapi
decis
regard
admiss
intens
care
unit
chang
demograph
composit
hivinfect
popul
may
lead
chang
outcom
hivposit
popul
age
exampl
inform
deriv
hospit
claim
databas
us
suggest
higher
case
fatal
rate
pneumonia
influenza
hivinfect
elderli
individu
compar
without
hiv
infect
pneumonia
import
caus
morbid
mortal
hivinfect
person
sever
intervent
reduc
risk
particular
smoke
cessat
immun
pneumococcu
influenza
offer
opportun
modifi
patient
risk
pneumonia
hivinfect
popul
continu
high
rate
exposur
cigarett
smoke
rate
pneumonia
higher
smoker
nonsmok
smoke
cessat
reduc
recent
systemat
review
literatur
de
et
al
found
current
smoker
increas
risk
bacteri
pneumonia
compar
nonsmok
hazard
ratio
confid
interv
risk
reduc
smoke
cessat
prospect
studi
franc
hazard
ratio
found
former
smoker
compar
current
smoker
use
medic
adjunct
smoke
cessat
extens
investig
hivuninfect
smoker
data
hivinfect
peopl
small
studi
safeti
toler
vareniclin
tartrat
hivposit
individu
found
high
frequenc
advers
event
commonli
nausea
excel
quit
rate
abstin
rate
week
advers
chang
hiv
viral
load
detect
given
high
incid
invas
pneumococc
diseas
hivinfect
person
efficaci
pneumococc
vaccin
atrisk
group
consider
interest
immun
pneumococcu
two
form
pneumococc
vaccin
pneumococc
polysaccharid
vaccin
pcv
develop
studi
one
random
trial
observ
studi
subject
recent
systemat
review
conclud
current
evid
base
lend
moder
support
efficaci
ppv
immun
random
trial
carri
africa
popul
without
widespread
access
art
high
mortal
rate
found
increas
rate
pneumonia
immun
group
howev
result
may
applic
popul
access
art
lower
background
rate
pneumococc
pneumonia
observ
studi
shown
immun
associ
reduc
rate
pneumococc
diseas
although
mani
studi
confound
factor
could
influenc
observ
complet
account
suffer
rel
poor
immunogen
particularli
low
count
one
studi
hivinfect
individu
found
antibodi
respons
declin
preimmun
level
month
observ
cohort
studi
canada
pneumococc
serotyp
isol
despit
fact
popul
receiv
immun
vaccin
failur
associ
low
count
pcv
theoret
advantag
induc
celldepend
immun
respons
demonstr
immunogen
hivinfect
adult
sever
studi
recent
review
nune
madhi
conclud
pcv
effect
reduc
rate
invas
pneumococc
diseas
produc
effect
durabl
antibodi
respons
individu
art
artnaiv
note
immun
respons
pneumococc
vaccin
significantli
better
higher
count
apart
possibl
direct
benefit
pneumococc
immun
vaccin
young
children
offer
protect
seven
common
serotyp
associ
indirect
benefit
hivinfect
individu
us
widespread
use
part
childhood
immun
schedul
associ
reduct
invas
pneumococc
diseas
caus
vaccin
serotyp
hivinfect
adult
chang
pneumococc
epidemiolog
follow
routin
childhood
immun
also
observ
popul
reduct
invas
pneumococc
diseas
caus
vaccin
serotyp
spain
howev
studi
also
note
increas
sever
need
mechan
ventil
pneumococc
pneumonia
work
south
africa
also
demonstr
reduc
level
pneumococc
carriag
follow
introduct
childhood
pcv
includ
reduct
amongst
unvaccin
adult
appear
reduct
nonvaccin
pneumococc
serotyp
restrict
hivinfect
individu
analysi
data
england
wale
sinc
introduct
childhood
immun
suggest
reduct
invas
pneumococc
diseas
caus
serotyp
target
vaccin
studi
found
invas
pneumococc
diseas
hivinfect
patient
caus
serotyp
would
cover
new
pcv
present
guidelin
british
hivassoci
recommend
pneumococc
polysaccharid
vaccin
hivinfect
individu
count
whilst
state
consid
individu
lower
count
note
efficaci
may
poorer
low
count
art
infecti
diseas
societi
america
recommend
combin
pneumococc
polysaccharid
immun
one
dose
follow
week
although
suggest
may
delay
blood
count
art
healtheconom
analysi
rozenbaum
et
al
conclud
addit
hivinfect
adult
england
would
cost
effect
smith
et
al
explor
current
recommend
us
conclud
singl
dose
pcv
may
costeffect
current
dual
immun
strategi
whilst
cho
et
al
report
current
recommend
would
still
costsav
note
studi
costeffect
sensit
assumpt
made
regard
vaccin
effect
howev
estim
costeffect
pneumococc
immun
limit
poor
uptak
pneumococc
immun
amongst
hivposit
adult
appear
immun
clinic
guidelin
us
uk
advis
immun
hivinfect
individu
influenza
vaccin
metaanalysi
beck
et
al
publish
studi
suggest
influenza
vaccin
effect
reduc
incid
influenza
well
toler
note
respiratori
comorbid
copd
common
hivinfect
individu
immun
individu
influenza
may
particularli
import
recent
work
suggest
immunogen
influenza
immun
hivinfect
person
may
improv
highdos
four
time
standard
trival
dose
vaccin
whilst
increas
dose
well
toler
clear
whether
enhanc
antibodi
respons
translat
better
clinic
costeffect
protect
cap
major
caus
morbid
mortal
amongst
hivinfect
individu
although
wealth
evid
attest
increas
rate
pneumonia
immunocompromis
individu
prior
use
art
clear
reduct
recent
year
hivinfect
popul
high
rate
smoke
comorbid
respiratori
patholog
current
data
suggest
hiv
infect
remain
independ
risk
factor
cap
present
known
whether
hivinfect
individu
increas
suscept
new
respiratori
pathogen
merscov
manag
outcom
pneumonia
hivinfect
individu
appear
differ
hivuninfect
person
sever
intervent
made
shown
reduc
risk
includ
use
art
achiev
undetect
plasma
hiv
load
smoke
cessat
uptak
pneumococc
influenza
immun
intern
guidelin
recommend
hivinfect
individu
despit
increas
knowledg
base
continu
uncertainti
regard
degre
increas
risk
pneumonia
hivinfect
individu
best
option
reduc
smoke
cessat
import
evid
requir
best
immun
strategi
popul
conflict
interest
marc
lipman
jame
brown
conflict
human
anim
right
inform
consent
articl
contain
studi
human
anim
subject
perform
author
